Schrödinger Raises Drug Discovery Revenue Guidance Amid Strong ACV Growth
Schrödinger (SDGR) reported strong third-quarter results characterized by sustained commercial momentum and significant growth in Annual Contract Value (ACV). The company's ACV grew by 17% overall, or 24% when excluding specific non-recurring contributions, signaling robust demand for its software platform. Based on this performance, management has updated its long-range outlook. The company now projects 2026 ACV to reach between $222 million and $232 million. Additionally, Schrödinger raised its drug discovery revenue guidance to a range of $75 million to $85 million, reflecting progress toward its strategic long-term goals.
Tickers: $SDGR
Topics: ACV growth earnings report management commentary revenue growth